Main Content

We develop life-transforming treatments for autoinflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways.

Please be advised that our lead product candidate, Coversin, was recently renamed nomacopan following its acceptance as an International Nonproprietary Name by the World Health Organization.